Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Rationale and design of the Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trial
Blood Pressure, Volume 20, No. 5, Year 2011
Notification
URL copied to clipboard!
Description
Background. Sub-Saharan Africa experiences an epidemic surge in hypertension. Studies in African Americans led to the recommendation to initiate antihypertensive treatment in Blacks with a diuretic or a low-dose fixed combination including a diuretic. We mounted the Newer versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trial to compare in native African patients a fixed combination of newer drugs, not involving a diuretic, with a combination of older drugs including a diuretic. Methods. Patients aged 3069 years with uncomplicated hypertension (140179/90109 mmHg) and two or fewer associated risk factors are eligible. After a 4-week run-in period off treatment, 180 patients will be randomized to once daily bisoprolol/hydrochlorothiazide 5/6.25 mg or amlodipine/valsartan 5/160 mg. To attain and maintain blood pressure below 140/90 mmHg during 6 months of follow-up, the doses of bisoprolol and amlodipine in the combination tablets will be increased to 10 mg/day with the possible addition of α-methyldopa or hydralazine. NOAAH is powered to demonstrate a 5-mmHg between-group difference in sitting systolic pressure with a two-sided p-value of 0.01 and 90% power. NOAAH is investigator-led and complies with the Helsinki declaration. Results. Six centers in four sub-Saharan countries started patient recruitment on September 1, 2010. On December 1, 195 patients were screened, 171 were enrolled, and 51 were randomized and followed up. The trial will be completed in the third quarter of 2011. Conclusions. NOAAH (NCT01030458) is the first randomized multicenter trial of antihypertensive medications in hypertensive patients born and living in sub-Saharan Africa. © 2011 Scandinavian Foundation for Cardiovascular Research.
Authors & Co-Authors
Odili, Augustine Nonso
Belgium, Leuven
Ku Leuven
Nigeria, Abuja
University of Abuja
Richart, Tom
Belgium, Leuven
Ku Leuven
Netherlands, Maastricht
Universiteit Maastricht
Thijs, Lutgarde B.
Belgium, Leuven
Ku Leuven
Kingue, Samuel
Cameroon, Yaounde
Yaounde General Hospital
Boombhi, Hilaire J.
Cameroon, Yaounde
Yaounde General Hospital
Lemogoum, Daniel
Cameroon, Douala
Douala School of Medicine
Kaptue, Joseph
Cameroon, Douala
Douala School of Medicine
Kamdem, Marius K.
Cameroon, Douala
Douala School of Medicine
Mipinda, Jean Bruno
Gabon, Libreville
Centre Hospitalier de Libreville
Omotoso, Babatunde A.
Nigeria, Ilorin
University of Ilorin
Kolo, Phillip Manma
Nigeria, Ilorin
University of Ilorin
Aderibigbe, Ademola O.
Nigeria, Ilorin
University of Ilorin
Ulasi, Ifeoma I.
Nigeria, Naukka
University of Nigeria
Anisiuba, Benedict Chukwuemeka
Nigeria, Naukka
University of Nigeria
Ijoma, Chinwuba K.
Nigeria, Naukka
University of Nigeria
Bâ, Serigne Abdou
Senegal, Dakar
Centre Hospitalier Universitaire Dakar
Ndiaye, Mouhamadou Bamba
Senegal, Dakar
Centre Hospitalier Universitaire Dakar
Staessen, Jan A.
Belgium, Leuven
Ku Leuven
Netherlands, Maastricht
Universiteit Maastricht
M'Buyamba-Kabangu, Jean René
Congo, Leuven
University Hospital of Kinshasa
Statistics
Citations: 19
Authors: 19
Affiliations: 10
Identifiers
Doi:
10.3109/08037051.2011.572614
ISSN:
08037051
e-ISSN:
16511999
Research Areas
Health System And Policy
Noncommunicable Diseases
Study Design
Cohort Study